These beneficial outcomes were accompanied by higher infiltration of CAR T cells (comb-CAR T cells) in both the peripheral blood on days 42 and 54 and harvested tumours than that in the AXL-CAR T group (mono-CAR T cells) (Fig. 4d–f), despite the dosage of CAR T cells that was twice higher in the latter group. Here, AXL is linked to neoplasm.